<div id="readability-page-1"><p>AngioDynamics (NASDAQ:ANGO - Get Free Report) is expected to be posting its  Q2 2026 results before the market opens on Tuesday, January 6th. Analysts expect AngioDynamics to post earnings of ($0.10) per share and revenue of $76.4330 million for the quarter. AngioDynamics has set its FY 2026 guidance at -0.330--0.230 EPS. Individuals may visit the the company's upcoming Q2 2026 earning results page for the latest details on the call scheduled for Tuesday, January 6, 2026 at 8:00 AM ET.</p><div><p><span></span><span>Get <strong>AngioDynamics</strong> alerts:</span></p></div><p>AngioDynamics (NASDAQ:ANGO - Get Free Report) last released its earnings results on Thursday, October 2nd. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.12) by $0.02. The firm had revenue of $75.71 million during the quarter, compared to analyst estimates of $72.69 million. AngioDynamics had a negative return on equity of 3.16% and a negative net margin of 10.67%.AngioDynamics's revenue was up 12.1% compared to the same quarter last year. During the same period last year, the business posted ($0.11) earnings per share.  On average, analysts expect AngioDynamics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year. </p><h2>AngioDynamics Price Performance</h2><p>ANGO stock opened at $12.87 on Tuesday. The business's 50-day moving average is $12.61 and its two-hundred day moving average is $10.91. The firm has a market capitalization of $530.24 million, a P/E ratio of -16.50 and a beta of 0.49. AngioDynamics has a 1 year low of $8.27 and a 1 year high of $13.99. </p><h2>Insider Activity</h2><p>In other news, CEO James C. Clemmer purchased 10,000 shares of the business's stock in a transaction on Thursday, October 9th. The shares were bought at an average price of $11.15 per share, with a total value of $111,500.00. Following the completion of the transaction, the chief executive officer directly owned 882,529 shares in the company, valued at approximately $9,840,198.35. This represents a 1.15% increase in their position. The purchase was disclosed in a filing with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, SVP Lawrence T. Weiss bought 10,000 shares of the stock in a transaction dated Tuesday, October 21st. The shares were acquired at an average price of $11.81 per share, for a total transaction of $118,100.00. Following the completion of the transaction, the senior vice president owned 93,597 shares of the company's stock, valued at approximately $1,105,380.57. The trade was a 11.96% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders have acquired 20,890 shares of company stock worth $239,532. Corporate insiders own  6.00% of the company's stock. </p><h2>Institutional Investors Weigh In On AngioDynamics</h2><p>A number of institutional investors and hedge funds have recently made changes to their positions in ANGO. State of Wyoming purchased a new stake in shares of  AngioDynamics in the second quarter valued at approximately $31,000.  Russell Investments Group Ltd. boosted its position in shares of  AngioDynamics by 329.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 4,188 shares of the medical instruments supplier's stock worth $47,000 after purchasing an additional 3,213 shares in the last quarter.  Tower Research Capital LLC TRC grew its stake in shares of  AngioDynamics by 359.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,457 shares of the medical instruments supplier's stock worth $54,000 after purchasing an additional 4,268 shares during the period.  BNP Paribas Financial Markets increased its holdings in shares of  AngioDynamics by 106.0% in the 3rd quarter. BNP Paribas Financial Markets now owns 7,473 shares of the medical instruments supplier's stock valued at $83,000 after purchasing an additional 3,846 shares in the last quarter.  Finally, Raymond James Financial Inc. purchased a new position in shares of  AngioDynamics in the 2nd quarter valued at about $90,000. 89.43% of the stock is owned by hedge funds and other institutional investors. </p><h2>Analyst Upgrades and Downgrades</h2><p>A number of equities research analysts have commented on the stock. Weiss Ratings  reissued a &#34;sell (d-)&#34; rating on shares of AngioDynamics in a research report on Wednesday, October 8th. Canaccord Genuity Group increased their target price on AngioDynamics from $17.00 to $18.00 and gave the company a &#34;buy&#34; rating in a report on Friday, October 3rd. Finally, Wall Street Zen cut AngioDynamics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Sunday, December 21st. Three research analysts have rated the stock with a Buy rating and one  has assigned  a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus price target of $19.33.</p><p><b>Check Out Our Latest Analysis on AngioDynamics</b></p><h2>AngioDynamics Company Profile</h2> (Get Free Report)<p>AngioDynamics, Inc is a medical technology company headquartered in Latham, New York, that develops, manufactures and markets a broad range of minimally invasive medical devices. The company's products focus on three core areas: vascular access, peripheral vascular intervention and interventional oncology. Its solutions are designed to improve procedural outcomes, reduce complications and enhance patient comfort in hospital and outpatient settings.  </p><p>In the vascular access segment, AngioDynamics offers a portfolio of devices including implanted ports, peripherally inserted central catheters (PICCs), hemodialysis catheters and specialty blood management products.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than AngioDynamics</li><li>Wall Street Stockpicker Names #1 Stock of 2026</li><li>Do not delete, read immediately</li><li>$100 Trillion “AI Metal” Found in American Ghost Town</li><li>Drop these 5 stocks now!</li><li>Trump’s new AI budget just passed — one stock could soar</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5HTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="325" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QU5HTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AngioDynamics Right Now?</h2><p>Before you consider AngioDynamics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AngioDynamics wasn't on the list.</p><p>While AngioDynamics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

ANGO

<p>AngioDynamics (NASDAQ: ANGO) is set to release its Q2 2026 earnings on January 6, with analysts expecting a loss of $0.10 per share and revenue of $76.43 million. The company has provided FY 2026 guidance of -0.330 to -0.230 EPS. Recent insider activity includes CEO James C. Clemmer purchasing 10,000 shares. Institutional investors have also increased their stakes in AngioDynamics, with 89.43% of the stock owned by hedge funds. Analysts have mixed ratings, with a consensus of "Moderate Buy."</p>

AngioDynamics (ANGO) to Release Earnings on Tuesday